Literature DB >> 19786138

N255 is a key residue for recognition by a monoclonal antibody which protects against Yersinia pestis infection.

Jim Hill1, Sophie Leary, Sophie Smither, Angus Best, Jonas Pettersson, Ake Forsberg, Bry Lingard, Alexandria Lipka, Katherine A Brown, E Diane Williamson, Richard W Titball.   

Abstract

Mab7.3 to Yersinia pestis LcrV antigen (LcrV(Ype)) protected J774A.1 macrophages in vitro from killing by a Yersinia pseudotuberculosis strain expressing LcrV(Ype). Of 4 site-directed mutations in the coiled-coil region (148-169) and 7 mutations in the 225-255 sequence of LcrV(Ype), only the mutation of N255 to D255, abrogated the binding of Mab7.3 and reduced its protective capacity against plague. Since the Mab7.3 epitope in LcrV(Ype) (135-275) encompasses a region (136-180) thought to be exposed on the injectisome, we suggest that Mab7.3 protects by binding to LcrV(Ype) and interfering with protein-protein interactions necessary for type three secretion.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19786138     DOI: 10.1016/j.vaccine.2009.09.061

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

Review 1.  Surface organelles assembled by secretion systems of Gram-negative bacteria: diversity in structure and function.

Authors:  David G Thanassi; James B Bliska; Peter J Christie
Journal:  FEMS Microbiol Rev       Date:  2012-05-24       Impact factor: 16.408

2.  Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines.

Authors:  Lauriane E Quenee; Nancy A Ciletti; Derek Elli; Timothy M Hermanas; Olaf Schneewind
Journal:  Vaccine       Date:  2011-07-16       Impact factor: 3.641

3.  Polymorphisms in the lcrV gene of Yersinia enterocolitica and their effect on plague protective immunity.

Authors:  Nathan C Miller; Lauriane E Quenee; Derek Elli; Nancy A Ciletti; Olaf Schneewind
Journal:  Infect Immun       Date:  2012-01-17       Impact factor: 3.441

Review 4.  Potential human immunotherapeutics for plague.

Authors:  Voahangy Andrianaivoarimanana; Lovasoa Nomena Randriantseheno; Kristoffer M Moore; Nicola J Walker; Steven G Lonsdale; Sarah Kempster; Neil A Almond; Minoarisoa Rajerison; E Diane Williamson
Journal:  Immunother Adv       Date:  2021-10-05

Review 5.  Protecting against plague: towards a next-generation vaccine.

Authors:  E D Williamson; P C F Oyston
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

6.  Dual-function antibodies to Yersinia pestis LcrV required for pulmonary clearance of plague.

Authors:  Nicholas A Eisele; Deborah M Anderson
Journal:  Clin Vaccine Immunol       Date:  2009-10-14

7.  Direct neutralization of type III effector translocation by the variable region of a monoclonal antibody to Yersinia pestis LcrV.

Authors:  Maya I Ivanov; Jim Hill; James B Bliska
Journal:  Clin Vaccine Immunol       Date:  2014-03-05

8.  Use of bioengineered human commensal gut bacteria-derived microvesicles for mucosal plague vaccine delivery and immunization.

Authors:  A L Carvalho; A Miquel-Clopés; U Wegmann; E Jones; R Stentz; A Telatin; N J Walker; W A Butcher; P J Brown; S Holmes; M J Dennis; E D Williamson; S G P Funnell; M Stock; S R Carding
Journal:  Clin Exp Immunol       Date:  2019-04-15       Impact factor: 4.330

9.  The role of immune correlates and surrogate markers in the development of vaccines and immunotherapies for plague.

Authors:  E D Williamson
Journal:  Adv Prev Med       Date:  2011-09-29

Review 10.  Antibiotic Therapy of Plague: A Review.

Authors:  Florent Sebbane; Nadine Lemaître
Journal:  Biomolecules       Date:  2021-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.